1. CARM1 Preferentially Methylates H3R17 over H3R26 through a Random Kinetic Mechanism
   Suzanne L. Jacques et al, 2016, Biochemistry CrossRef
2. Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs
   Kathy A. Gelato et al, 2016, Expert Opinion on Therapeutic Targets CrossRef
3. Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma
   Allison E. Drew et al, 2017, Sci Rep CrossRef
4. CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis
   Sarah M. Greenblatt et al, 2018, Cancer Cell CrossRef
5. Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 Against Acute Myeloid Leukemia
   Zuhao Guo et al, 2019, J. Med. Chem. CrossRef
6. Differential CARM1 Isoform Expression in Subcellular Compartments and among Malignant and Benign Breast Tumors
   David Shlensky et al, 2015, PLoS ONE CrossRef
7. null
   Thomas B. Nicholson et al, 2015 CrossRef
8. null
   Amit K. Behera et al, 2019 CrossRef
9. Transition state mimics are valuable mechanistic probes for structural studies with the arginine methyltransferase CARM1
   Matthijs J. van Haren et al, 2017, Proc Natl Acad Sci USA CrossRef
10. AMPK-ERK/CARM1 Signaling Pathways Affect Autophagy of Hepatic Cells in Samples of Liver Cancer Patients
    Qiu-Fang Qin et al, 2019, Front. Oncol. CrossRef
11. Structural and biochemical evaluation of bisubstrate inhibitors of protein arginine N-methyltransferases PRMT1 and CARM1 (PRMT4)
    Emma A. Gunnell et al, 2020 CrossRef
12. null
    Matthijs J. van Haren et al, 2019 CrossRef
13. Protein arginine methylation/demethylation and cancer
    Coralie Poulard et al, 2016, Oncotarget CrossRef
14. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas
    Kylee J. Veazey et al, 2020, Leukemia CrossRef
15. Epigenetic Aberrations in Multiple Myeloma.
    Cinzia Caprio et al, 2020, Cancers (Basel) CrossRef
16. Arginine Methylation in Brain Tumors: Tumor Biology and Therapeutic Strategies
    Jean-Paul Bryant et al, 2021, Cells CrossRef
17. Protein arginine methyltransferases and hepatocellular carcinoma: A review
    Yu Lei et al, 2021, Translational Oncology CrossRef
18. Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy
    Zhuqing Zhang et al, 2021, J. Med. Chem. CrossRef
19. Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5
    Yizhen Tian et al, 2021, Toxicology and Applied Pharmacology CrossRef
20. Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker
    Yingqi Qiu et al, 2022, BMC Genom Data CrossRef
21. Expression of pluripotency-related genes in human glioblastoma
    Álvaro Fabrício Lopes Rios et al, 2022 CrossRef
22. Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction–Reconstruction and Fragment-Growing Approach
    Giulia Iannelli et al, 2022, J. Med. Chem. CrossRef
23. Protein Arginine Methyltransferases (PRMTs): Orchestrators of Cancer Pathogenesis, Immunotherapy Dynamics, and Drug Resistance
    Yihang Gao et al, 2024, Biochemical Pharmacology CrossRef
24. Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma
    Zhihao Liu et al, 2024, J. Med. Chem. CrossRef
25. Tyrosine phosphorylation of CARM1 promotes its enzymatic activity and alters its target specificity
    Hidehiro Itonaga et al, 2024, Nat Commun CrossRef